LAUSR

Arber, D.A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M.J., Le Beau, M.M., Bloomfield, C.D., Cazzola, M. & Vardiman, J.W. (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391–2405. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189–199. Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Löwenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791–4797. Cluzeau, T., Mounier, N., Karsenti, J.M., Richez, V., Legros, L., Gastaud, L., Garnier, G., Re, D., Montagne, N., Gutnecht, J., Gabriel Fuzibet, J., Auberger, P., Raynaud, S. & Cassuto, J.P. (2013) Monosomal karyotype improves IPSS‐R stratification in MDS and AML patients treated with Azacitidine. American Journal of Hematology, 88, 780–783. Della Porta, M.G., Picone, C., Tenore, A., Yokose, N., Malcovati, L., Cazzola, M. & Ogata, K. (2014) Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. Haematologica, 99, e8–e10. Fenaux, P., Mufti, G.J., Hellstrom‐Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study. The Lancet Oncology, 10, 223–232. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia‐Manero, G., Solé, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstöcker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454–65. Kuendgen, A., Müller‐Thomas, C., Lauseker, M., Haferlach, T., Urbaniak, P., Schroeder, T., Brings, C., Wulfert, M., Meggendorfer, M., Hildebrandt, B., Betz, B., Royer‐Pokora, B., Gattermann, N., Haas, R., Germing, U. & Götze, K.S. (2018) Efficacy of azacitidine is independent of molecular and clinical characteristics‐an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature. Oncotarget, 9, 27882– 27894. Ogata, K., Nakamura, K., Yokose, N., Tamura, H., Tachibana, M., Taniguchi, O., Iwakiri, R., Hayashi, T., Sakamaki, H., Murai, Y., Tohyama, K., Tomoyasu, S., Nonaka, Y., Mori, M., Dan, K. & Yoshida, Y. (2002) Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood, 100, 3887– 3896. Papageorgiou, S.G., Vasilatou, D., Kontos, C.K., Kotsianidis, I., Symeonidis, A., Galanopoulos, A.G., Hatzimichael, E., Megalakaki, A., Poulakidas, E., Diamantopoulos, P., Vassilakopoulos, T.P., Zikos, P., Papadaki, H., Mparmparousi, D., Bouronikou, E., Panayiotidis, P., Viniou, N.A. & Pappa, V. (2018) The prognostic value of monosomal karyotype (MK) in higher‐risk patients with myelodysplastic syndromes treated with 5‐Azacitidine: a retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. American Journal of Hematology, 93, 895–901. Wells, D.A., Benesch, M., Loken, M.R., Vallejo, C., Myerson, D., Leisenring, W.M. & Deeg, H.J. (2003) Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood, 102, 394–403.